Clinical Trials Logo

Carcinoid Tumor clinical trials

View clinical trials related to Carcinoid Tumor.

Filter by:

NCT ID: NCT00602082 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Start date: August 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as capecitabine, streptozocin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving capecitabine together with streptozocin is more effective with or without cisplatin in treating neuroendocrine tumors. PURPOSE: This randomized phase II trial is studying giving capecitabine together with streptozocin to see how well it works compared with or without cisplatin in treating patients with unresectable or metastatic neuroendocrine tumors.

NCT ID: NCT00590343 Completed - Clinical trials for Metastatic Neuroendocrine Tumors

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

PTK787
Start date: November 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine if PTK787/ZK222584 (vatalanib) will stabilize or decrease rising biochemical markers along with progressive disease or syndrome symptoms in patients with metastatic neuroendocrine tumors.

NCT ID: NCT00580320 Completed - Melanoma Clinical Trials

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Start date: September 2004
Phase: Phase 1
Study type: Interventional

Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.

NCT ID: NCT00510068 Completed - Clinical trials for Advanced Neuroendocrine Tumors of Pancreatic Origin

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

RADIANT-3
Start date: July 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.

NCT ID: NCT00454363 Completed - Clinical trials for Pancreatic Polypeptide Tumor

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00446082 Completed - Acromegaly Clinical Trials

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Start date: June 2006
Phase: Phase 1
Study type: Interventional

This study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease

NCT ID: NCT00434109 Completed - Clinical trials for Neuroendocrine Tumor

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.

NCT ID: NCT00427349 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Start date: November 7, 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.

NCT ID: NCT00424723 Completed - Clinical trials for Neuroendocrine Tumors

Pemetrexed in Patients With Advanced Neuroendocrine Tumors

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects (good and bad) pemetrexed has on patients with advanced neuroendocrine tumors.

NCT ID: NCT00416767 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Start date: May 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works as first-line therapy in treating patients with locally advanced or metastatic neuroendocrine tumors of the duodenum or pancreas that cannot be removed by surgery.